Lam Research Corp. (LRCX)

Lam Research Corp. (LRCX) rose 6.07% in the latest session, but the stock is still 46.21% below its 52-week high of $438.50 and sits below its 50-day and 200-day moving averages ($280.09 and $284.01). The move comes after a sharp decline over the past month, with the stock down 23.80% over one month and 27.67% over three months, even though it is up 48.18% over the past year. For investors the question is whether the rebound can hold above the 20-day EMA of $240.99, which is the first level a rise would meet. Analysts remain strongly supportive: 30 of 34 rate the stock Buy or Strong Buy, and the median 12-month target is $352.50. CleaRank's own rating is Hold, which reflects the weak price trend and a valuation that is broadly in line with peers.

Shares rose 6.07% in the latest session, and the stock is up 6.53% over one week. The volume on that session was 27.9% below its average, which means the bounce came on lighter trading than usual. That matters because a rebound on thin volume is less convincing than one backed by heavy buying. The stock is still down 23.80% over one month and 27.67% over three months, so the rebound has only partly reversed the recent fall. Over one year the stock is up 48.18%, which shows how sharply sentiment has swung.

Lam Research has beaten the EPS estimate in each of the last seven reports, and the October 21, 2026 report reported adjusted EPS of $2.20 against an estimate of $2.18. Despite that beat, the share price fell 11.76% in the first session after the report. The July 29, 2026 report was followed by the largest first-session move among the last eight reports, a gain of 17.98%. Across the last seven reports, the stock beat the EPS estimate every time, yet the share price fell in the first session after three of them and rose after four. The pattern shows that the stock trades on expectations for the next quarter more than on the beat itself.

Of the 34 analysts with a current rating, 30 rate the stock Buy or Strong Buy, 4 rate it Hold, and none rate it Sell. Three months ago, 29 of 35 ratings were Buy, so the share of Buy ratings has held up. On October 22, 2026, UBS, Citigroup, Mizuho, Needham and Morgan Stanley all kept their ratings, and B. Riley Securities kept its Buy rating on November 9, 2026. The median 12-month target is $352.50, 49.4% above the price, and the target range runs from $255.00 to $500.00.

The trailing P/E is 35.15, almost exactly the sector median of 35.1, so the valuation is broadly in line with peers. The company reports a net profit margin of 32.3% and an operating margin of 39.95%, against a return on equity of 70.12%, far above the sector median of 13.4%. The debt-to-equity ratio is 0.27. Revenue grew 29.99% in the latest quarter year on year, faster than the sector median of 24.2%.

The base case is a stock that stays volatile while it works back toward its moving averages. The 20-day EMA at $240.99 is the first test, and a close above the 50-day SMA at $280.09 would be the first sign that the downtrend is losing ground. Earnings momentum is the main support: analysts expect fiscal-year EPS to rise 65.8% to $9.65, and revenue to grow 52.3% to $35.4B. Against that, the stock fell 11.76% in the first session after the October 21, 2026 report despite a beat, so the market is weighing more than the headline EPS. Analyst targets range from $255.00 to $500.00, with a median of $352.50. A move toward the median would require the price to reclaim the 200-day SMA at $284.01 first. A failure to hold $240.99 would bring the 52-week low of $135.50 back into view as a reference point, although that level is far below current trading.

Support sits at the 52-week low of $135.50, the furthest level below the price and the last line of defence on the chart. No support sits closer to the price, so the 52-week low of $135.50 is the nearest level below. Resistance begins at the 20-day EMA of $240.99, which is just above the price and the first level a rise would meet. Next is the 50-day SMA at $280.09, followed by the 200-day SMA at $284.01, where the two long-term averages cluster. The 52-week high of $438.50 is the furthest resistance.